Akari Therapeutics (AKTX) Net Income towards Common Stockholders (2014 - 2026)
Akari Therapeutics (AKTX) reported Net Income towards Common Stockholders of -$14.5 million for Q1 2026, down 290.15% on a YoY basis from $7.6 million in Q1 2025, and down 172.84% sequentially from -$5.3 million in Q4 2025.
Akari Therapeutics (AKTX) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has 9 years of Net Income towards Common Stockholders data on file, last reported at -$14.5 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 290.15% year-over-year to -$14.5 million; the trailing twelve-month figure through Mar 2026 stood at -$29.4 million (down 64.84% YoY), and the FY2025 full-year result was -$17.3 million, up 12.6% from the prior year.
- Net Income towards Common Stockholders slipped to -$14.5 million in Q1 2026, from -$5.3 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$2.5 million in Q3 2023 to a low of -$14.5 million in Q1 2026.
- A 4-year average of -$5.4 million and a median of -$4.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders soared 56.77% in 2025 and slumped 290.15% in 2026, its largest moves.
- Tracing AKTX's Net Income towards Common Stockholders over 4 years: stood at -$5.1 million in 2023, then grew by 26.05% to -$3.8 million in 2024, then tumbled by 40.46% to -$5.3 million in 2025, then plunged by 172.84% to -$14.5 million in 2026.
- Business Quant data shows AKTX's Net Income towards Common Stockholders at -$14.5 million in Q1 2026, -$5.3 million in Q4 2025, and -$6.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 205.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.46 Mn |
| Dec 31, 2025 | -5.30 Mn |
| Sep 30, 2025 | -6.40 Mn |
| Jun 30, 2025 | -3.22 Mn |
| Mar 31, 2025 | -3.71 Mn |
| Dec 31, 2024 | -3.77 Mn |
| Sep 30, 2024 | -2.90 Mn |
| Jun 30, 2024 | -7.45 Mn |
| Mar 31, 2024 | -5.99 Mn |
| Dec 31, 2023 | -5.10 Mn |
| Sep 30, 2023 | -2.49 Mn |
| Jun 30, 2023 | -4.59 Mn |
| Mar 31, 2023 | -4.56 Mn |
| Dec 31, 2020 | -6.89 Mn |
| Sep 30, 2020 | -240,751.00 |
| Jun 30, 2020 | -5.91 Mn |
| Mar 31, 2020 | -4.93 Mn |
| Dec 31, 2019 | -7.82 Mn |
| Sep 30, 2019 | -3.12 Mn |
| Jun 30, 2019 | -6.03 Mn |